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Abstract
The consequences of infection by Suid 
herpesvirus type 1 (SuHV-1) that causes 
Aujeszky’s disease (AD) are well studied, 
however, the effects of immunomodulators 
(IMs) of microbial origin (viral and bacterial) 
when administered solely or in combination 
with the attenuated SuHV-1 vaccine are less 
known. The effects of parenteral administration 
of IMs, inactivated Parapoxvirus ovis (P. ovis) or 
a combination of inactivated Propionibacterium 
granulosum (P. granulosum) and detoxified 
Escherichia coli lipopolysaccharide (LPS) and 
attenuated SuHV-1, strain Bartha, on the 
proportion of peripheral blood CD3- CD21+ B 
cells were analysed in 30 crossbred, 3-month 
old pigs using flow cytometry (FCM). 
Specific antibodies for gE and gB of SuHV-
1 were detected using the enzyme-linked 
immunosorbent assay (ELISA). Data were 
compared among six experimental groups: (1) 
pigs that separately received the vaccine, (2) 
IM of bacterial origin, (3) IM of viral origin, (4) 
simultaneous administration of the vaccine and 
bacterial IM, (5) simultaneous administration 
of the vaccine and viral IM, and (6) the control 
group of untreated pigs. Comparison of B 
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cell proportions and the detection of specific 
antibodies in blood samples of vaccinated 
pigs on Day 11 of the experiment showed a 
transient decrease in B cell proportion, though 
this could not be assumed to be related since 
the control group showed a decrease in B cell 
content on the same day. The results showed 
that the use of IMs alone or in combination 
with the attenuated SuHV-1 vaccine did not 
have a significant impact on the proportion of 
peripheral blood B cells in growing pigs. 
Key words: B cells; pigs; flow cytometry; 
immunomodulators; Aujeszky disease
Introduction
Numerous studies have confirmed 
that immunomodulators (IMs) of 
various origin (yeast derivatives, plant 
extracts and animal by-products) not 
only improve the production results in 
breeding and fattening of food animals, 
but may also stimulate a stronger non-
specific immune response (Gallois and 
Oswald, 2008), especially in stress periods 
such as weaning of piglets (Li et al., 2005; 
Nofrarias et al., 2006; Zomborszky-Kovács 
et al., 2006; Nofrarias et al., 2007; Valpotić 
et al., 2016). Although, the effects of IMs 
administered together with vaccines 
against swine viral diseases have been 
investigated in numerous studies (Hiss et 
al., 2003; Biuk-Rudan et al., 2004; Terzić 
et al., 2004; Fraile et al., 2012; Šperanda et 
al., 2013), the mechanisms of their action 
are not yet fully clear.
IMs can be used alone or in combination 
with other substances with similar effects. 
For example, when Propionibacterium 
granulosum (P. granulosum) and 
Escherichia coli lipopolysaccharide (LPS) 
co-administered, they have a positive 
immunoregulatory effect on porcine 
innate immunity, i.e. NK cell activity and 
an early immune response which may 
contribute to protection against viral 
infections. Pigs that received PG/LPS 
had increased growth rate, and the PG/
LPS combination proved to possess good 
adjuvant effects by enhancing the immune 
response to a vaccine prepared with the 
inactivated microorganism Mycoplasma 
hyopneumoniae and a vaccine with 
attenuated classical swine fever virus. It 
could be administered concomitantly in 
the field with vaccines, thus improving 
both non-specific and specific immune 
responses to enhance porcine resistance 
to infection (Lo et al., 2009).
Numerous studies of IMs of microbial 
origin have also been conducted with 
certain viruses. Biuk-Rudan et al. 
(2004) investigated the nonspecific 
immunoprophylactic effect in pigs when 
chemically inactivated Parapoxvirus ovis 
(P. ovis), strain D 1701 was administered 
(106.75 TCID50/dose) and compared it with 
the results obtained in pigs vaccinated 
with gE- vaccine against Aujeszky’s 
disease (AD) and those obtained in control 
pigs after exposure to an experimental 
infection with a wild-type AD virus 
(Northern Ireland Aujeszky’s-3, NIA-3). 
The IM did not affect the production of 
specific antibodies, making it less effective 
than vaccines in AD immunoprophylaxis. 
However, stimulating results were 
obtained as clinical signs of disease such 
as fever, spring frequency and weight 
loss were reduced or prevented. 
Studies have been performed of the 
effect of P. ovis, strain D 1701, alone and 
in combination with other viral vaccines. 
The results of a study with a subunit 
E2 vaccine against classical swine fever 
administered concomitantly with P. ovis 
(strain D1701) as an IM showed that its 
effect was evident on T lymphocytes but 
not on B lymphocytes in piglets (Terzić et 
al., 2004).
The adaptive immune and the innate 
immune systems are intimately bound 
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together to ensure that an effective 
immune response occurs in response to 
microbial invasion. While it is possible 
for some viruses and many pathogenic 
bacteria to be taken up by dendritic cells, 
other mechanisms have been developed 
to recognize pathogens that lack the 
appropriate markers for recognition. 
Lymphocytes overcome the constraints 
placed on the innate immune system by 
recognizing an almost infinite diversity 
of antigens, thus targeting each pathogen 
specifically (Thacker, 2004). B cells are 
cells that, like T lymphocytes, originate 
from the lymphoid lineage of bone 
marrow cells, but mature in secondary 
lymphatic organs such as bone marrow, 
lymph nodes, spleen, and Payer plates. 
B cells are an essential component of the 
adaptive immune system and provide 
antibody-mediated protection against 
infections. After stimulation of surface 
immunoglobulin receptors, and in some 
cases co-stimulatory T helper cell-derived 
signals, they respond with proliferation 
and affinity maturation of the antigen 
receptor, and finally differentiate into 
circulating memory B cells or antibody-
producing plasma cells (Braun et al., 
2017). B cells specifically recognize 
antigens using the B-Cell Receptor (BCR). 
If B cells have not previously been in 
contact with the antigen, they must also 
be activated first, though unlike T cells, B 
cells can respond to the antigen directly 
without being previously shown as part 
of the Major Histocompatibility Complex 
(MHC). 
The marker of B lymphocyte lineage is 
not known as for T cells, but studies have 
shown that porcine B lymphocytes can 
express multiple molecules such as CD2, 
CD25, CD21, IgM, SLA-DR, CD45RC, 
CD5 (Šinkora et al., 1998; Šinkora et al., 
2003; Wilson and Wilkie, 2007) and mAb-
reactive molecules for human CD79α, 
CD20 and CD86 molecules (Jones et al., 
1993; Faldyna et al., 2007). The expression 
of these molecules differs during the 
foetal and postnatal life of pigs, as well as 
during the maturation and differentiation 
of B lymphocytes.
In general, inactivated B lymphocytes 
are thought to express IgM, CD2 and 
CD21 molecules and to lose CD21 
molecule expression upon activation 
or contact with a foreign antigen. The 
CD21 molecule with the CD19 and 
CD81 molecules forms a complex that 
together with the BCR enables the 
activation of B lymphocytes. It is also 
a type 2 complement receptor, i.e., it 
binds the degradation products of the C3 
component of the complement system 
and promotes the antigen presentation 
on B lymphocytes (Zabel and Weis, 2001). 
Plasmablasts originating from activated 
B lymphocytes also lose the expression 
of the IgM molecule, which after the 
transition to plasma cells lose the 
expression of the CD2 molecule. Memory 
B lymphocytes also lose CD2 molecule 
expression but retain IgM molecule 
expression (Šinkora and Butler, 2009).
Although AD has been eradicated 
in domestic pigs in many countries, 
Suid herpesvirus type 1 (SuHV-1) is 
still present in wild boar populations, 
as seen by serological surveillance and 
virus isolation (Hahn et al., 2010; Müller 
et al., 2010; Boadella et al., 2012). The 
same authors concluded that infected 
wild boars pose a constant threat for the 
transmission of SuHV-1 to domestic pigs.
Marker vaccines against AD usually 
contain SuHV-1, which lacks one or 
more viral envelope glycoproteins 
or a viral enzyme, or genes encoding 
these glycoproteins/enzymes. The 
development of diagnostic tests that 
allow for the differentiation of serum 
antibodies induced by virulent strains of 
SuHV-1 and marker vaccines against AD 
has also made it possible to distinguish 
between infected and vaccinated pigs 
(Van Oirschot et al., 1986).
The purpose of this study was to gain 
insight into the effects of the studied IMs 
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of microbial origin and the vaccine on 
changes in the proportion of peripheral 
blood B cells, as this could be useful in 
future research on the use of IMs of 
microbial origin as adjuvants for vaccines 
against AD and, thus, could expand 
the current applications of IMs in pig 
farming.
Materials and methods 
Animals 
The study was performed on 30 
commercial crossbred pigs without 
antibodies for the AD virus. At the 
beginning of the study, pigs were about 
three months old, of both sexes and 
with an average bodyweight (bw) of 24 
kg. All pigs were marked with ear tags 
and randomly assigned into six separate 
groups of five pigs each, followed by 
a seven-day period of acclimatization. 
They were fed ad libitum with commercial 
feed for fattening pigs and clinically 
monitored daily. Immune status, i.e., the 
presence of antibodies for glycoproteins B 
(gB) and E (gE) of AD virus was checked 
by the enzyme-linked immunosorbent 
assay (ELISA).
Vaccine and immunomodulators
All veterinary-medicinal products 
(VMPs) used during the experiment, 
i.e., two commercial VMPs of microbial 
origin with immunomodulatory effect 
and the vaccine, have been authorized 
for use in pigs in the Republic of 
Croatia. Both IMs and the vaccine 
were injected into the neck muscles 
according to the protocol listed in 
Table 1.
Vaccination was performed with a 
vaccine against AD (VAD, Genera d.d., 
Croatia) that contains attenuated AD 
virus (SuHV-1, Bartha strain K/61 gE-) 
and which has been in use in Croatia 
for decades. The reconstituted vaccine 
contains at least 104.5 TCID50 per 1 mL.
The immunomodulator of viral 
origin (IMV, Zoetis SA, Belgium) contains 
inactivated P. ovis, strain D1701, and 1 
mL contains the amount of virus that in 
vitro stimulates the formation of at least 
230 interferon units.
The immunomodulator of bacterial 
origin (IMB, Laboratorios Calier, Spain) 
contains LPS of Escherichia coli (0.02 mg/
mL) and inactivated P. granulosum (0.25 
mg/mL). 
The study was conducted in 
accordance with ethical principles and 
approved by the institutional ethics 
committee and ethics committee of the 
Croatian Ministry of Agriculture (records 
No.: UP/I-322-01/14-01/86, file No.: 525-
10/0255-14-2).
Table 1. Administration of the IMs (IMV or IMB) and VAD with blood sampling 
Applied IMV* and IMB**, VAD*** and blood sampling () according to the days (D) of the 
experiment 
Group D1 D4 D7 D11 D18
1. IMB  IMB, VAD   
2. IMB  IMB   
3. IMV  IMV, VAD   
4. IMV  IMV   
5.  VAD   
6.  -   
* 2 mL/animal; ** 1 mL/10 kg bw; *** 1 mL/animal
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Blood sampling and sample 
preparation 
Blood samples were collected by 
venepuncture from the anterior vena cava 
on Days 1, 7, 11 and 18 of the experiment. 
Blood (10 mL) for the detection of 
serum antibodies against gE and gB 
of SuHV-1 was collected into sterile 
tubes without an anticoagulant. 
After blood clotting in tubes without 
an anticoagulant, sera were further 
separated by centrifugation at 2500 rpm 
for 10 minutes (Rotina 420, Hettich, 
Germany) and stored in new tubes, after 
which they were ready for analysis.
Blood samples (6 mL) for isolation 
of peripheral blood mononuclear cells 
(PBMCs) were collected in sterile tubes 
containing the anticoagulant lithium 
heparin. Isolation of PBMCs from 
peripheral blood samples was performed 
according to Andrišić et al. (2020). 
Detection of serum antibodies for gE 
and gB SuHV-1
Commercial ELISA tests HerdChek 
Anti-PRV gpI (IDEXX Laboratories, USA) 
and HerdChek Anti-PRV gB (IDEXX 
Laboratories, USA) were used to detect 
serum antibodies to gE (former name 
gI) and gB of SuHV-1. Samples were 
analysed according to the manufacturer’s 
instructions, and the absorbance 
was measured at 650 nm using a 
spectrophotometer (Tecan Sunrise Basic, 
Austria). Results were expressed as 
sample/negative (S/N) value and the 
test results were interpreted as follows: 
serum sample contains antibodies to gE 
and gB of SuHV-1 if S/N is less than or 
equal to 0.60; a sample is suspect if S/N is 
less than or equal to 0.70 and greater than 
0.60; and serum sample does not contain 
antibodies for gE and gB of SuHV-1 if S/N 
is greater than 0.70.
The presence of antibodies to gE and 
gB indicates exposure to the field strains 
of SuHV-1 and/or vaccine containing gE 
antigen.
Immunophenotyping of PBMCs
Isolated PBMCs were defrosted in a 
water bath (38 °C), washed twice in RPMI 
1640 medium and counted in each sample 
using a Bürker-Türk haemocytometer. 
The samples of PBMCs were then washed 
in phosphate-buffered saline (PBS) buffer 
solution and dead cells were stained 
with Zombie Aqua™ Fixable Viability 
Dye (BioLegend, USA) according to 
the manufacturer’s instructions. After 
washing in PBS, the samples were 
adjusted to 2.5 x 106 PBMC/mL and 180 
μL of each PBMC sample was transferred 
into tubes for fluorescence-activated cell 
sorting (FACS). Then, PBMC were mixed 
with mouse serum IgG (Invitrogen, 
USA) to block unspecific staining, and 
monoclonal antibodies (mAbs) were 
added. These mAbs were commercially 
available and were specific for porcine 
CD3 (epitope ε) and CD21 were directly 
stained with fluorochromes (mAb for CD3 
with Alexa Fluor® 405; Novus Biologicals, 
USA and mAb for CD21 R-phycoerythrin; 
Southern Biotech, USA). After 30 minutes 
of incubation at 4 °C, the labelled PBMCs 
were washed in PBS and fixed with 2% 
(w/v) formaldehyde in PBS (pH=7.4).
Flow cytometry analysis (FCM) 
The FCM analysis of labelled PBMCs 
was performed using a BD LSR II 
flow cytometer (BD Biosciences, USA) 
equipped with 405 nm, 488 nm and 640 
nm lasers. Live individual lymphocytes 
(1 x 104 per sample) were acquired 
using FACSDiva Software Version 5.0.3 
(BD Biosciences, USA). After that, the 
proportion of B cells (CD3-CD21+) within 
lymphocytes was analysed. Raw data 
were analysed by Flow Jo Software 
Version 7.6.5 (FlowJo, LCC, USA), and 
the results are shown in Figure 1.
Statistical analysis
Statistical analysis was performed 
using Stata version 13.1 (STATA Corp., 
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USA). Using ANOVA, the relative 
values of the proportion of B cells were 
compared among all groups of animals at 
each sampling (post-hoc Tukey’s test). The 
observed differences in relative values of 
B cells between time points within the 
same group were verified by repeated 
measures ANOVA (post-hoc paired 
t-test). Statistical analysis of results that 
did not follow normal distribution was 
performed using Kruskal-Wallis test. 
The results of statistical comparison, i.e., 
P values less than 0.05 were considered 
statistically significant.
Results and Discussion
When the immune status was checked 
in the serum samples of the pigs selected 
for the experiment, antibodies for gB and 
gE of SuHV-1 (R > 0.70) were not detected 
at the beginning of the study (Day 1) or 
after the second blood collection (Day 
7). In the current study, the absence of 
specific antibodies for SuHV-1 at the 
beginning of the experiment served only 
to confirm that the pigs had not been 
exposed to the AD virus from the field 
or that they originated from vaccinated 
sows. After the third blood collection 
(Day 11), antibodies for gB of SuHV-1 
(S/N < 0.60) and no antibodies for gE of 
SuHV-1 (S/N > 0.70) were detected in the 
serum of vaccinated pigs (pigs in the 1st, 
3rd, and 5th groups), whereas antibodies 
for neither gB of SuHV-1 nor gE of SuHV-
1 (S/N > 0.70) were present in the sera of 
the pigs in the 2nd, 4th, and 6th groups. 
After the fourth blood collection (Day 18), 
the finding of SuHV-1-specific antibodies 
was similar to that after Day 11.
Since the marker for pig B 
lymphocytes is not well established, they 
were immunophenotypically defined 
in this experiment as lymphocytes that 
do not express the T cell marker (CD3) 
Fig. 1. Gating strategy for FCA: gating was first applied to (A) single PBMC based on FSC-H (Forward 
Scatter-Hight) and FSC-A (Forward Scatter-Area), then to (B) live PBMC based on labelling with Zombie 
Aqua™ and then to (C) lymphocytes based on SSC-A (Side Scatter - Area) and FSC-A. (D) Lymphocytes 
were then analysed for expression of CD3 (CD3 AF 405 - Alexa Fluor® 405) and CD21 (CD21 FE - 
phycoerythrin) cell surface differentiation antigens
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but express the CD21 molecule (CD3-
CD21+). Although the CD21 molecule is 
not specific only for B lymphocytes, it 
can be assumed with high probability 
that pigs PBMC in the lymphocyte Gate 
expressing the CD21 molecule are B 
lymphocytes, since this molecule in pigs 
is also expressed on follicular dendritic 
cells that can be mostly found in lymph 
nodes (Piriou-Guzylack and Salmon, 
2008). 
At the beginning of this experiment, 
the mean value of the proportion of 
B cells within total peripheral blood 
lymphocytes (PBL) for all groups was 
similar to that for crossbred pigs of a 
similar age (6.9%), as reported by Terzić 
et al. (2002).
The mean value of the proportion of 
B cells within PBL (Table 2) for all groups 
of pigs at the first day of the experiment 
was 5.93%. The dynamics of the mean 
value of the B cells content in all groups 
was similar throughout the experiment, 
i.e., an increase between Day 1 and Day 
7, a decrease between Day 7 and Day 
11, and an increase between Day 11 and 
Day 18. Only group 4 showed a decrease 
in the mean value of the proportion of B 
lymphocytes between Day 11 and Day 
18. However, no statistically significant 
differences were found in the mean value 
of the B cell content between groups 
during the period of blood sampling, 
nor between individual days of blood 
sampling in the same groups (Table 2).
On Day 11, a transient decrease was 
recorded in the mean value of the B cells 
proportion in all groups receiving the 
vaccine, and on Day 11, serum antibodies 
for gB of SuHV-1 were detected for 
the first time in those same groups. 
These findings could indicate higher 
activation of B cells and transformation 
to plasmablasts. According to Šinkora 
and Butler (2009), after contact with 
the antigen, B cells transform into 
plasmablasts that lose the expression 
of the CD21 molecule. However, this 
finding could not be confirmed in our 
study because the control group also 
recorded a decrease of B cell proportion 
on Day 11. These results were obtained 
according to the predicted experimental 
protocol; however, earlier or later and 
more frequent blood sampling for 
cytometric analysis after the application 
of the investigated IMs, could give more 
precise answers about their effect on B 
cell kinetics in growing pigs.
Our observations and the presented 
results could be useful to complement the 
existing knowledge and to plan the future 
research of adjuvant effects of IMs in pigs 
vaccinated with the attenuated virus. 
Experimental infection would give more 
accurate results. However, as this was 
only a pilot study, additional research 
Table 2. Kinetic of proportions of B cells (CD3-CD21+) within PBL in the experimental groups of pigs at 
days of blood sampling
Mean value and standard deviation of the mean value (% ± SD)/day of sampling (D)
Group D1 D7 D11 D18
1. (IMB+VAD) 5.66 ± 4.23 9.74 ± 4.57 5.10 ± 2.37 6.54 ± 1.22
2. (IMB) 5.75 ± 2.92 7.82 ± 2.30 4.79 ± 3.15 4.57 ± 1.47
3. (IMV+VAD) 6.29 ± 3.37 7.43 ± 1.21 4.59 ± 0.89 7.28 ± 3.44
4. (IMV) 5.24 ± 1.71 5.40 ± 2.39 6.13 ± 2.11 4.65 ± 1.76
5. (VAD) 6.56 ± 3.65 10.53 ± 5.70 8.66 ± 5.63 10.01 ± 5.75
6. (CG*) 6.11 ± 3.02 9.87 ± 3.29 4.96 ± 1.84 6.13 ± 2.78
* Control group
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and measurement tools are required to 
establish correlations between B cells and 
antibody levels in the peripheral blood of 
pigs. 
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Posljedice infekcije herpes virusom-1 svinja 
(SuHV-1) uzročnikom bolesti Aujeszkoga (BA) 
dobro su istražene, ali manje je poznat učinak 
imunomodulatora (IM) mikrobnog podrijetla 
(virusnog ili bakterijskog) primijenjenih u kom-
binaciji s atenuiranim cjepivom protiv BA. Uči-
nak parenteralne primjene IM-a, inaktiviranog 
virusa Parapoxvirus ovis ili kombinacije inakti-
virane bakterije Propionibacterium granulosum i 
lipopolisaharida bakterije Escherichia coli i cjepi-
va koje sadržava atenuirani virus BA (SuHV-1, 
soj Bartha) na udio CD3-CD21+ B limfocita pe-
riferne krvi analiziran je protočnom citometri-
jom u krvi 30 komercijalnih križanaca svinja u 
dobi od tri mjeseca bez protutijela za virus BA. 
Prisustvo je protutijela za glikoproteine B (gB) 
i E (gE) virusa BA provjereno imunoenzimnim 
testom (engl. Enzyme Linked Immunosorbant 
Assay, ELISA). Dobiveni su rezultati uspoređe-
ni između 6 pokusnih skupina tj. između svinja 
koje su primile: cjepivo (1. skupina), IM bakte-
rijskog podrijetla (2. skupina), IM virusnog po-
drijetla (3. skupina), svinja koje su istovremeno 
primile cjepivo i IM bakterijskog podrijetla (4. 
skupina) ili cjepivo i IM viruisnog podrijetla 
(5. skupina) te netretirane, kontrolne skupine 
svinja (6. skupina). Usporedba udjela B limfo-
cita u uzorcima krvi cijepljenih svinja 11. dan 
pokusa pokazali su prolazno smanjenje sred-
nje vrijednosti udjela B limfocita za koje se nije 
moglo pretpostaviti da je povezano s pojavom 
specifičnih protutijela, jer je smanjenje srednje 
vrijednosti udjela B limfocita bilo i u kontrolnoj 
skupini istoga dana. Naši su rezultati pokazali 
da primjena samo IM-a, kao i njihovih kombi-
nacija s atenuiranim cjepivom protiv BA, nisu 
imali značajan utjecaj na udio B limfocita peri-
ferne krvi u tovljene prasadi. 
Ključne riječi: B limfociti, svinje, protočna 
citometrija, imunomodulatori, bolest Aujeszkoga
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